Abstract
We explored activity and safety of a dose-dense/dose-intense adriamycin, bleomycin, vinblastine and dacarbazine regimen (ABVDDD-DI) in 82 patients with advanced Hodgkin Lymphoma. Patients entered a two-stage Bryant-Day Phase II study to receive six cycles of ABVDDD-DI without consolidation radiotherapy. Cycles were supported with granulocyte colony-stimulating factor and delivered every 21 d; drugs were administered on days 1 and 11 at the same doses of standard ABVD except for doxorubicin (35 mg/m2; first four cycles only). Co-primary endpoints were complete response (CR) rate and severe acute cardiopulmonary toxicity; secondary endpoints were event-free (EFS) and disease-free survival (DFS). All patients received the four doxorubicin-intensified courses and 96% concluded all six cycles (82·3% within the intended 18 weeks). This translated into a 66·9% increase of received dose-intensity for doxorubicin and 31·8% for the other agents over standard ABVD. The CR rate was 95·1% (78/82) and 87·8% (72/82) achieved a metabolic CR after two cycles. Cardiopulmonary toxicity never exceeded grade 2 and affected 14·6% of patients. Most frequent toxicities were grade 4 neutropenia (10%) and anaemia (9%), grade 3 infection (17%) and grade 2 mucocutaneous changes (30%). Five-year EFS and DFS was 88·3% and 93·7%, respectively. ABVDDD-DI regimen was well-tolerated and ensured substantial CR and EFS rates without radiotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 118-129 |
| Number of pages | 12 |
| Journal | British Journal of Haematology |
| Volume | 166 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- ABVD
- Dose intensity
- Doxorubicin
- Hodgkin lymphoma
- Radiotherapy
ASJC Scopus subject areas
- Hematology
Cite this
A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. / Russo, Filippo; Corazzelli, Gaetano; Frigeri, Ferdinando; Capobianco, Gaetana; Aloj, Luigi; Volzone, Francesco; De Chiara, Annarosaria; Bonelli, Annamaria; Gatani, Tindaro; Marcacci, Gianpaolo; Donnarumma, Daniela; Becchimanzi, Cristina; de Lutio, Elisabetta; Ionna, Franco; De Filippi, Rosaria; Lastoria, Secondo; Pinto, Antonello.
In: British Journal of Haematology, Vol. 166, No. 1, 2014, p. 118-129.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma
AU - Russo, Filippo
AU - Corazzelli, Gaetano
AU - Frigeri, Ferdinando
AU - Capobianco, Gaetana
AU - Aloj, Luigi
AU - Volzone, Francesco
AU - De Chiara, Annarosaria
AU - Bonelli, Annamaria
AU - Gatani, Tindaro
AU - Marcacci, Gianpaolo
AU - Donnarumma, Daniela
AU - Becchimanzi, Cristina
AU - de Lutio, Elisabetta
AU - Ionna, Franco
AU - De Filippi, Rosaria
AU - Lastoria, Secondo
AU - Pinto, Antonello
PY - 2014
Y1 - 2014
N2 - We explored activity and safety of a dose-dense/dose-intense adriamycin, bleomycin, vinblastine and dacarbazine regimen (ABVDDD-DI) in 82 patients with advanced Hodgkin Lymphoma. Patients entered a two-stage Bryant-Day Phase II study to receive six cycles of ABVDDD-DI without consolidation radiotherapy. Cycles were supported with granulocyte colony-stimulating factor and delivered every 21 d; drugs were administered on days 1 and 11 at the same doses of standard ABVD except for doxorubicin (35 mg/m2; first four cycles only). Co-primary endpoints were complete response (CR) rate and severe acute cardiopulmonary toxicity; secondary endpoints were event-free (EFS) and disease-free survival (DFS). All patients received the four doxorubicin-intensified courses and 96% concluded all six cycles (82·3% within the intended 18 weeks). This translated into a 66·9% increase of received dose-intensity for doxorubicin and 31·8% for the other agents over standard ABVD. The CR rate was 95·1% (78/82) and 87·8% (72/82) achieved a metabolic CR after two cycles. Cardiopulmonary toxicity never exceeded grade 2 and affected 14·6% of patients. Most frequent toxicities were grade 4 neutropenia (10%) and anaemia (9%), grade 3 infection (17%) and grade 2 mucocutaneous changes (30%). Five-year EFS and DFS was 88·3% and 93·7%, respectively. ABVDDD-DI regimen was well-tolerated and ensured substantial CR and EFS rates without radiotherapy.
AB - We explored activity and safety of a dose-dense/dose-intense adriamycin, bleomycin, vinblastine and dacarbazine regimen (ABVDDD-DI) in 82 patients with advanced Hodgkin Lymphoma. Patients entered a two-stage Bryant-Day Phase II study to receive six cycles of ABVDDD-DI without consolidation radiotherapy. Cycles were supported with granulocyte colony-stimulating factor and delivered every 21 d; drugs were administered on days 1 and 11 at the same doses of standard ABVD except for doxorubicin (35 mg/m2; first four cycles only). Co-primary endpoints were complete response (CR) rate and severe acute cardiopulmonary toxicity; secondary endpoints were event-free (EFS) and disease-free survival (DFS). All patients received the four doxorubicin-intensified courses and 96% concluded all six cycles (82·3% within the intended 18 weeks). This translated into a 66·9% increase of received dose-intensity for doxorubicin and 31·8% for the other agents over standard ABVD. The CR rate was 95·1% (78/82) and 87·8% (72/82) achieved a metabolic CR after two cycles. Cardiopulmonary toxicity never exceeded grade 2 and affected 14·6% of patients. Most frequent toxicities were grade 4 neutropenia (10%) and anaemia (9%), grade 3 infection (17%) and grade 2 mucocutaneous changes (30%). Five-year EFS and DFS was 88·3% and 93·7%, respectively. ABVDDD-DI regimen was well-tolerated and ensured substantial CR and EFS rates without radiotherapy.
KW - ABVD
KW - Dose intensity
KW - Doxorubicin
KW - Hodgkin lymphoma
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84902327159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902327159&partnerID=8YFLogxK
U2 - 10.1111/bjh.12862
DO - 10.1111/bjh.12862
M3 - Article
C2 - 24673727
AN - SCOPUS:84902327159
VL - 166
SP - 118
EP - 129
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 1
ER -